The Pharmacology of Amphetamine and Methylphenidate: Relevance to the Neurobiology of Attention-Deficit/Hyperactivity Disorder and Other Psychiatric Comorbidities

Amphetamine and Methylphenidate Are Not Interchangeable Tools but Distinct Pharmacological Instruments Acting on Overlapping but Non-Identical Neural Substrates

Faraone’s 2018 systematic review accomplishes something that no clinical guideline or meta-analysis of effect sizes can: it forces the reader to reckon with the molecular specificity of two drugs routinely treated as interchangeable first-line options. Amphetamine inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocks vesicular monoamine transporter 2 (VMAT-2) to liberate dopamine from vesicular storage, reverses DAT to push cytosolic dopamine into the synapse, and inhibits monoamine oxidase—a four-pronged assault on monoamine clearance. Methylphenidate, by contrast, inhibits DAT and NET but does not reverse the transporter; it redistributes VMAT-2 rather than blocking it, and it possesses agonist activity at the serotonin 5-HT1A receptor, a target with established relevance to anxiety and mood regulation. These are not differences of degree. They are differences of kind, operating at the vesicular, cytosolic, enzymatic, and receptor levels simultaneously. The review marshals preclinical microdialysis data showing that amphetamine elevates extracellular striatal dopamine more dramatically than methylphenidate, yet PET studies using [11C]raclopride demonstrate comparable reductions in D2 receptor binding potential—a dissociation that implies fundamentally different compartmental dynamics. Volkow’s PET work, cited extensively here, provides the human evidence anchoring this claim: therapeutic oral doses of methylphenidate significantly increase extracellular dopamine in the human brain, but the subjective and neurochemical profiles diverge from amphetamine in ways that the field has yet to translate into prescribing algorithms.

The Catecholamine-Deficit Model of ADHD Is Necessary but Radically Insufficient

The review’s deeper contribution is its quiet demolition of the catecholamine hypothesis as a sufficient explanatory framework. Faraone catalogs evidence implicating glutamate, opioid, serotonin, and acetylcholine systems in both ADHD pathophysiology and stimulant pharmacodynamics. Amphetamine enhances cellular responses to mGluR5 agonists, modulates μ-opioid receptor binding in the hypothalamus and amygdala, and produces time-dependent changes in cerebellar GABA, serotonin, and norepinephrine. Methylphenidate’s 5-HT1A agonism is not a pharmacological footnote—it is a direct point of contact with circuits governing anxiety and emotional regulation. Genome-wide copy number variation studies have linked metabotropic glutamate receptor gene networks to ADHD, and proton MRS studies reveal altered glutamate/glutamine ratios in adults with the disorder. This multi-transmitter architecture resonates with the broader reconceptualization advanced by Gabor Maté in Scattered Minds, where ADHD is understood not as a discrete dopamine deficit but as a developmental perturbation of self-regulatory systems shaped by environment and temperament. Where Maté offers the phenomenological and developmental lens, Faraone provides the molecular one, and together they converge on a picture in which ADHD is a systems-level disorder irreducible to a single neurotransmitter axis. The review also extends into territory occupied by Bessel van der Kolk’s work on how trauma alters catecholamine regulation and reward circuitry—circuits that overlap substantially with the corticostriatal networks Faraone identifies as structurally and functionally compromised in ADHD.

Comorbidity Is Not a Complication of ADHD but a Window into Its Neurobiology

The review’s most clinically urgent argument concerns psychiatric comorbidity. Faraone does not treat depression, anxiety, substance use disorder, and sleep disturbance as complications to be managed around ADHD treatment; he treats them as expressions of overlapping neurobiological substrates that stimulant pharmacology directly engages. Methylphenidate’s 5-HT1A agonism positions it as potentially anxiolytic through mechanisms shared with buspirone and certain SSRIs, while amphetamine’s opioid-system interactions—demonstrated by reduced μ-opioid receptor binding in preclinical models and endogenous opioid release in human PET studies—implicate reward and hedonic circuits with direct relevance to substance use disorder. The review notes that genetic studies have identified shared risk alleles between ADHD and its comorbidities, reinforcing the thesis that these conditions share etiological substrates rather than merely co-occurring by chance. This framing resonates with the reward-deficiency syndrome model elaborated by Blum and colleagues, where ADHD, addiction, and mood dysregulation are phenotypic expressions of a common genetic vulnerability in reward circuitry. It also connects to the structural neuroimaging data Faraone synthesizes: reduced gray matter volume in basal ganglia, anterior cingulate cortex, and dorsolateral prefrontal cortex in ADHD maps directly onto circuits implicated in depression (anterior cingulate), anxiety (amygdala-prefrontal connectivity), and addiction (ventral striatum).

The Default-Mode Network and the Pharmacology of Attention Are Two Faces of the Same Problem

One of the review’s most conceptually rich elements is its integration of network-level neuroscience with molecular pharmacology. The default-mode network (DMN), whose anticorrelation with task-positive networks is weakened in ADHD, is not merely an imaging finding—it is a functional signature of the failure of catecholamine-modulated circuits to properly toggle between internally and externally directed cognition. Methylphenidate normalizes this toggling, increasing activation in parietal and prefrontal cortices while increasing deactivation in the insula and posterior cingulate cortex. This is not symptom suppression; it is circuit-level restoration. The DMN dysregulation model connects directly to Allan Schore’s work on right-hemisphere affect regulation, where the capacity to shift between self-referential and externally-oriented processing is understood as a developmental achievement dependent on early relational experience and its neurobiological substrates. Faraone’s pharmacological data thus provide a molecular mechanism for what Schore describes phenomenologically: the failure of attentional and affective regulation as a systems-level breakdown rather than a localized deficit.

This review matters because it occupies a unique position: rigorous enough in its pharmacology to serve neuroscientists, yet structured to reveal clinical implications that most pharmacology reviews ignore. For anyone working at the intersection of ADHD, addiction, mood disorders, and developmental psychopathology, Faraone provides the molecular grammar without which the clinical conversation remains imprecise. No other single source maps the divergent mechanisms of the two most prescribed psychostimulants onto the multi-network, multi-transmitter architecture of ADHD and its comorbidities with this degree of systematic evidence.